BioSpace News Archive

Transgene and BioInvent International AB announce that the first patient of the Phase I part B clinical trial evaluating the combination of BT-001 and MSD’s anti-PD-1 therapy, KEYTRUDA® has been dosed.

BioInvent International AB and Transgene announce that that the first patient of the Phase 1 part B clinical trial evaluating the combination of BT-001 and MSD’s anti-PD-1 therapy, KEYTRUDA® has been dosed.

Bayer AG announced the opening of its first Cell Therapy Launch Facility in Berkeley, California to create the capacity to bring cell therapies to patients on a global scale.

Swedish biotech company Salipro Biotech AB and Estonian biotechnology company Icosagen announced that they entered into a multi-target antibody research agreement to advance drug discovery programs against several challenging membrane proteins, including G protein-coupled receptors and solute carrier transporters.

Oculis Holding AG announced that Professor Ramin Tadayoni, M.D., Ph.D., presented the positive results from Stage 1 of the Phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress, which took place October 5-8, 2023 in Amsterdam, the Netherlands.

A slate of new initiatives to support locally led innovation was announced in Dakar by the Bill & Melinda Gates Foundation and its partners at the Grand Challenges Annual Meeting.

Mallinckrodt plc announced the publication of two journal manuscripts reinforcing the clinical and economic evidence supporting the efficacy, safety profile, continued use, and cost-effectiveness of Acthar Gel for appropriate patients across a range of FDA-approved autoimmune and inflammatory disease indications.

Zevra Therapeutics, Inc. today announced that Neil F. McFarlane has been named President and Chief Executive Officer of Zevra and appointed to the Board of Directors, effective October 10, 2023.

OrthoPediatrics Corp. announced the limited release of the DF2® Brace as part of its expansion in the non-surgical business for treating kids with musculoskeletal injuries.

Renovaro Biosciences Inc. is pleased to announce the appointment of Leni Boeren and Ruud Hendriks as Independent Directors.